Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Rating of “Moderate Buy” from Analysts

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has been given a consensus rating of “Moderate Buy” by the six analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $43.25.

Several research analysts have recently commented on LYEL shares. Robert W. Baird set a $49.00 target price on Lyell Immunopharma and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Needham & Company LLC set a $45.00 target price on Lyell Immunopharma in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Finally, Citizens Jmp started coverage on Lyell Immunopharma in a research note on Monday, March 9th. They set a “market outperform” rating and a $34.00 target price for the company.

Lyell Immunopharma Stock Performance

NASDAQ:LYEL opened at $11.97 on Friday. The company has a market cap of $279.31 million, a PE ratio of -0.87 and a beta of -0.09. Lyell Immunopharma has a 52-week low of $8.46 and a 52-week high of $45.00. The stock has a 50-day simple moving average of $19.87 and a 200 day simple moving average of $23.42.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.10). The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%. On average, research analysts predict that Lyell Immunopharma will post -7.87 earnings per share for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Hedge funds have recently added to or reduced their stakes in the company. BBR Partners LLC acquired a new position in Lyell Immunopharma in the 4th quarter valued at $210,000. ExodusPoint Capital Management LP acquired a new position in Lyell Immunopharma in the 4th quarter valued at $262,000. Marshall Wace LLP acquired a new position in Lyell Immunopharma in the 2nd quarter valued at $94,000. Jane Street Group LLC acquired a new position in Lyell Immunopharma in the 4th quarter valued at $382,000. Finally, Barclays PLC raised its holdings in Lyell Immunopharma by 1,239.5% in the 4th quarter. Barclays PLC now owns 15,967 shares of the company’s stock valued at $491,000 after acquiring an additional 14,775 shares in the last quarter. 66.05% of the stock is owned by institutional investors and hedge funds.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.